The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients
Open accessAbstract
BACKGROUND: Previous studies have independently validated the prognostic relevance of residual cancer burden (RCB) after neoadjuvant chemotherapy. We used results from several independent cohorts in a pooled patient-level analysis to evaluate the relationship of RCB with long-term prognosis across different phenotypic subtypes of breast cancer, to assess generalisability in a broad range of practice settings. METHODS: In this pooled analysis, 12 institutes and trials in Europe and the USA were identified by personal communications with site investigators. We obtained participant-level RCB results, and data on clinical and pathological stage, tumour subtype and grade, and treatment and follow-up in November, 2019, from patients (aged ≥18 years) with primary stage I-III breast cancer treated with neoadjuvant chemotherapy followed by surgery. We assessed the association between the continuous RCB score and the primary study outcome, event-free survival, using mixed-effects Cox models with the incorporation of random RCB and cohort effects to account for between-study heterogeneity, and stratification to account for differences in baseline hazard across cancer subtypes defined by hormone receptor status and HER2 status. The association was further evaluated within each breast cancer subtype in multivariable analyses incorporating random RCB and cohort effects and adjustments for age and pretreatment clinical T category, nodal status, and tumour grade. Kaplan-Meier estimates of event-free survival at 3, 5, and 10 years were computed for each RCB class within each subtype. FINDINGS: We analysed participant-level data from 5161 patients treated with neoadjuvant chemotherapy between Sept 12, 1994, and Feb 11, 2019. Median age was 49 years (IQR 20-80). 1164 event-free survival events occurred during follow-up (median follow-up 56 months [IQR 0-186]). RCB score was prognostic within each breast cancer subtype, with higher RCB score significantly associated with worse event-free survival. The univariable hazard ratio (HR) associated with one unit increase in RCB ranged from 1·55 (95% CI 1·41-1·71) for hormone receptor-positive, HER2-negative patients to 2·16 (1·79-2·61) for the hormone receptor-negative, HER2-positive group (with or without HER2-targeted therapy; p<0·0001 for all subtypes). RCB score remained prognostic for event-free survival in multivariable models adjusted for age, grade, T category, and nodal status at baseline: the adjusted HR ranged from 1·52 (1·36-1·69) in the hormone receptor-positive, HER2-negative group to 2·09 (1·73-2·53) in the hormone receptor-negative, HER2-positive group (p<0·0001 for all subtypes). INTERPRETATION: RCB score and class were independently prognostic in all subtypes of breast cancer, and generalisable to multiple practice settings. Although variability in hormone receptor subtype definitions and treatment across patients are likely to affect prognostic performance, the association we observed between RCB and a patient's residual risk suggests that prospective evaluation of RCB could be considered to become part of standard pathology reporting after neoadjuvant therapy. FUNDING: National Cancer Institute at the US National Institutes of Health.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
ELSTON, C. W., & ELLIS, I. O. (1991) · Histopathology · doi:10.1111/j.1365-2559.1991.tb00229.x · Cited by 6,175
Cortazar, P., Zhang, L., Untch, M., Mehta, K., Costantino, J. P., Wolmark, N., Bonnefoi, H., Cameron, D., Gianni, L., Valagussa, P., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62422-8 · Cited by 4,742
Self-citationWolff, A. C., Hammond, M. E. H., Hicks, D. G., Dowsett, M., McShane, L. M., Allison, K. H., Allred, D. C., Bartlett, J. M. S., Bilous, M., Fitzgibbons, P., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.50.9984 · Cited by 4,030
Self-citationTrastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer
von Minckwitz, G., Huang, C.-S., Mano, M. S., Loibl, S., Mamounas, E. P., Untch, M., Wolmark, N., Rastogi, P., Schneeweiss, A., Redondo, A., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1814017 · Cited by 2,625
Fisher, B., Bauer, M., Margolese, R., Poisson, R., Pilch, Y., Redmond, C., Fisher, E., Wolmark, N., Deutsch, M., Montague, E., et al. (1985) · New England Journal of Medicine · doi:10.1056/nejm198503143121101 · Cited by 2,194
Effect of preoperative chemotherapy on the outcome of women with operable breast cancer.
Fisher, B., Bryant, J., Wolmark, N., Mamounas, E., Brown, A., Fisher, E. R., Wickerham, D. L., Begovic, M., DeCillis, A., Robidoux, A., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.8.2672 · Cited by 2,165
Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy
Masuda, N., Lee, S.-J., Ohtani, S., Im, Y.-H., Lee, E.-S., Yokota, I., Kuroi, K., Im, S.-A., Park, B.-W., Kim, S.-B., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1612645 · Cited by 1,888
Measurement of Residual Breast Cancer Burden to Predict Survival After Neoadjuvant Chemotherapy
Symmans, W. F., Peintinger, F., Hatzis, C., Rajan, R., Kuerer, H., Valero, V., Assad, L., Poniecka, A., Hennessy, B., Green, M., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.10.6823 · Cited by 1,654
Self-citationCurigliano, G., Burstein, H. J., Winer, E. P., Gnant, M., Dubsky, P., Loibl, S., Colleoni, M., Regan, M. M., Piccart-Gebhart, M., Senn, H.-J., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx308 · Cited by 1,205
Neoadjuvant Versus Adjuvant Systemic Treatment in Breast Cancer: A Meta-Analysis
Mauri, D., Pavlidis, N., & Ioannidis, J. P. A. (2005) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dji021 · Cited by 1,200
Cited by
Advances in systemic therapies for triple negative breast cancer
Leon-Ferre, R. A., & Goetz, M. P. (2023) · BMJ · doi:10.1136/bmj-2022-071674 · Cited by 507
Self-citationShah, M., Osgood, C. L., Amatya, A. K., Fiero, M. H., Pierce, W. F., Nair, A., Herz, J., Robertson, K. J., Mixter, B. D., Tang, S., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-1110 · Cited by 105
Breast cancer: miRNAs monitoring chemoresistance and systemic therapy
Singh, S., Saini, H., Sharma, A., Gupta, S., Huddar, V. G., & Tripathi, R. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1155254 · Cited by 25
Metadata
- Authors
- Yau, C., Osdoit, M., van der Noordaa, M., Shad, S., Wei, J., de Croze, D., Hamy, A.-S., Laé, M., Reyal, F., Sonke, G. S., Steenbruggen, T. G., van Seijen, M., Wesseling, J., Martín, M., del Monte-Millán, M., López-Tarruella, S., Adamson, K., Albain, K. S., Asare, A. L., Asare, S. M., Balassanian, R., Beckwith, H., Berry, S. M., Berry, D. A., Boughey, J. C., Buxton, M. B., Chen, Y.-Y., Chen, B., Chien, A. J., Chui, S. Y., Clark, A. S., Clennell, J. L., Datnow, B., DeMichele, A. M., Duan, X., Edmiston, K. K., Elias, A. D., Ellis, E. D., Esserman, L. L., Euhus, D. M., Fadare, O., Fan, F., Feldman, M. D., Forero-Torres, A., Haley, B. B., Han, H. S., Harada, S., Haugen, P., Helsten, T., Hirst, G. L., Hylton, N. M., Isaacs, C., Kemmer, K., Khan, Q. J., Khazai, L., Klein, M. E., Krings, G., Lang, J. E., LeBeau, L. G., Leyland-Jones, B., Liu, M. C., Lo, S., Lu, J., Magliocco, A., Matthews, J. B., Melisko, M. E., Mhawech-Fauceglia, P., Moulder, S. L., Murthy, R. K., Nanda, R., Northfelt, D. W., Ocal, I. T., Olopade, O., Pambuccian, S., Paoloni, M., Park, J. W., Parker, B. A., Perlmutter, J., Peterson, G., Pusztai, L., Rendi, M., Rugo, H. S., Sahoo, S., Sams, S., Sanil, A., Sattar, H., Schwab, R. B., Singhrao, R., Steeg, K., Stringer-Reasor, E., Symmans, W. F., Tawfik, O., Tripathy, D., Troxell, M. L., van't Veer, L. J., Venters, S. J., Vinh, T., Viscusi, R. K., Wallace, A. M., Wei, S., Wilson, A., Yau, C., Yee, D., Zeck, J. C., Boughey, J. C., Goetz, M. P., Hoskin, T., Gould, R., Valero, V., Edge, S. B., Abraham, J. E., Bartlett, J. M. S., Caldas, C., Dunn, J., Earl, H., Hayward, L., Hiller, L., Provenzano, E., Sammut, S.-J., Thomas, J. S., Cameron, D., Graham, A., Hall, P., Mackintosh, L., Fan, F., Godwin, A. K., Schwensen, K., Sharma, P., DeMichele, A. M., Cole, K., Pusztai, L., Kim, M.-O., van 't Veer, L. J., Esserman, L. J., & Symmans, W. F.
- Venue
- The Lancet Oncology
- Publisher
- Elsevier BV
- Published
- 2022-01
- Volume
- 23
- Issue
- 1
- Pages
- 149-160
- ISSN
- 1470-2045 (ISSN-L)
- OpenAlex
- W4200028620
- Cited by
- 456
- References
- 25
- FWCI
- 20.46
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients. https://app.cochat.ai/papers/10.1016/s1470-2045(21)00589-1
- The paper
- Yau, C., Osdoit, M., van der Noordaa, M., Shad, S., Wei, J., de Croze, D., Hamy, A.-S., Laé, M., Reyal, F., Sonke, G. S., Steenbruggen, T. G., van Seijen, M., Wesseling, J., Martín, M., del Monte-Millán, M., López-Tarruella, S., Adamson, K., Albain, K. S., Asare, A. L., . . . Symmans, W. F. (2022). Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients. The Lancet Oncology. https://doi.org/10.1016/s1470-2045(21)00589-1
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.